Protalix Cost Of Revenue vs Total Revenue Analysis

PLX Stock  USD 1.83  0.07  3.98%   
Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Cost Of Revenue and its Total Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Cost Of Revenue vs Total Revenue

Cost Of Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Cost Of Revenue account and Total Revenue. At this time, the significance of the direction appears to have strong relationship.
The correlation between Protalix Biotherapeutics' Cost Of Revenue and Total Revenue is 0.77. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Cost Of Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Protalix Biotherapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Cost Of Revenue i.e., Protalix Biotherapeutics' Cost Of Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.77
Relationship DirectionPositive 
Relationship StrengthSignificant

Cost Of Revenue

Cost of Revenue is found on Protalix Biotherapeutics income statement and represents the costs associated with goods and services Protalix Biotherapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Revenue

Total revenue comprises all receipts Protalix Biotherapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.
Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 287.5 K in 2024, despite the fact that Discontinued Operations is likely to grow to (206.5 K).
 2021 2022 2023 2024 (projected)
Total Revenue38.4M47.6M65.5M68.8M
Depreciation And Amortization1.1M1.1M1.2M1.7M

Protalix Biotherapeutics fundamental ratios Correlations

0.040.19-0.240.850.570.95-0.030.00.45-0.640.620.990.60.040.46-0.22-0.160.50.410.490.560.090.020.380.23
0.040.440.16-0.220.33-0.120.520.49-0.27-0.24-0.02-0.02-0.030.130.34-0.390.12-0.430.260.29-0.390.140.49-0.28-0.1
0.190.440.56-0.10.190.090.050.39-0.43-0.470.160.180.30.020.13-0.56-0.2-0.10.350.65-0.080.150.42-0.27-0.35
-0.240.160.56-0.38-0.36-0.290.130.15-0.19-0.350.14-0.19-0.04-0.35-0.44-0.45-0.31-0.30.320.16-0.31-0.10.15-0.08-0.58
0.85-0.22-0.1-0.380.340.95-0.32-0.310.63-0.410.620.870.67-0.050.310.15-0.120.690.150.360.66-0.05-0.270.560.34
0.570.330.19-0.360.340.410.420.050.31-0.280.460.430.59-0.110.97-0.250.470.180.220.240.220.670.010.20.6
0.95-0.120.09-0.290.950.41-0.27-0.160.5-0.50.60.960.650.050.340.02-0.180.620.260.50.63-0.04-0.140.390.24
-0.030.520.050.13-0.320.42-0.270.460.04-0.290.07-0.12-0.08-0.110.36-0.620.36-0.130.39-0.27-0.020.540.220.030.11
0.00.490.390.15-0.310.05-0.160.46-0.57-0.4-0.370.0-0.340.610.04-0.7-0.25-0.330.650.0-0.2-0.040.72-0.5-0.49
0.45-0.27-0.43-0.190.630.310.50.04-0.57-0.230.820.430.5-0.680.270.110.110.550.02-0.080.490.19-0.510.780.69
-0.64-0.24-0.47-0.35-0.41-0.28-0.5-0.29-0.4-0.23-0.55-0.65-0.360.08-0.150.760.5-0.17-0.72-0.28-0.25-0.01-0.27-0.370.2
0.62-0.020.160.140.620.460.60.07-0.370.82-0.550.590.75-0.720.38-0.24-0.010.530.250.320.490.31-0.290.680.53
0.99-0.020.18-0.190.870.430.96-0.120.00.43-0.650.590.540.070.32-0.19-0.270.520.410.490.57-0.030.030.380.13
0.6-0.030.3-0.040.670.590.65-0.08-0.340.5-0.360.750.54-0.370.59-0.040.220.620.180.40.540.39-0.350.440.44
0.040.130.02-0.35-0.05-0.110.05-0.110.61-0.680.08-0.720.07-0.37-0.060.03-0.17-0.220.150.04-0.13-0.330.45-0.6-0.49
0.460.340.13-0.440.310.970.340.360.040.27-0.150.380.320.59-0.06-0.140.530.150.130.220.160.67-0.020.130.63
-0.22-0.39-0.56-0.450.15-0.250.02-0.62-0.70.110.76-0.24-0.19-0.040.03-0.140.250.07-0.79-0.03-0.04-0.3-0.57-0.050.25
-0.160.12-0.2-0.31-0.120.47-0.180.36-0.250.110.5-0.01-0.270.22-0.170.530.250.1-0.33-0.060.070.76-0.180.020.51
0.5-0.43-0.1-0.30.690.180.62-0.13-0.330.55-0.170.530.520.62-0.220.150.070.10.080.080.980.16-0.440.480.46
0.410.260.350.320.150.220.260.390.650.02-0.720.250.410.180.150.13-0.79-0.330.08-0.070.180.030.470.05-0.29
0.490.290.650.160.360.240.5-0.270.0-0.08-0.280.320.490.40.040.22-0.03-0.060.08-0.070.070.040.07-0.19-0.05
0.56-0.39-0.08-0.310.660.220.63-0.02-0.20.49-0.250.490.570.54-0.130.16-0.040.070.980.180.070.16-0.360.450.4
0.090.140.15-0.1-0.050.67-0.040.54-0.040.19-0.010.31-0.030.39-0.330.67-0.30.760.160.030.040.160.080.220.5
0.020.490.420.15-0.270.01-0.140.220.72-0.51-0.27-0.290.03-0.350.45-0.02-0.57-0.18-0.440.470.07-0.360.08-0.31-0.42
0.38-0.28-0.27-0.080.560.20.390.03-0.50.78-0.370.680.380.44-0.60.13-0.050.020.480.05-0.190.450.22-0.310.41
0.23-0.1-0.35-0.580.340.60.240.11-0.490.690.20.530.130.44-0.490.630.250.510.46-0.29-0.050.40.5-0.420.41
Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets45.4M67.9M73.7M55.8M84.4M51.0M
Other Current Liab11.9M13.9M15.2M10.6M15.3M16.0M
Total Current Liabilities40.2M86.5M33.2M32.4M45.5M47.8M
Net Debt43.1M46.1M(5.5M)16.4M2.6M2.8M
Cash17.8M18.3M39.0M17.1M23.6M31.8M
Non Current Assets Total12.9M12.2M12.0M10.9M14.5M9.6M
Cash And Short Term Investments17.8M38.5M39.0M22.2M44.6M33.7M
Net Receivables4.7M2M3.4M4.6M5.3M3.1M
Common Stock Shares Outstanding14.8M29.1M44.1M48.5M82.4M86.5M
Liabilities And Stockholders Equity45.4M67.9M73.7M55.8M84.4M51.0M
Non Current Liabilities Total75.5M8.5M46.5M34.0M5.3M5.1M
Other Current Assets698K2.1M1.3M1.3M1.1M1.6M
Total Liab115.7M95.0M79.7M66.4M50.9M56.1M
Total Current Assets32.5M55.7M61.7M44.9M69.9M42.5M
Short Long Term Debt Total60.9M64.4M33.5M33.5M26.3M51.9M
Total Stockholder Equity(70.3M)(27.0M)(6.0M)(10.6M)33.6M35.2M
Property Plant And Equipment Net11.0M10.4M9.9M9.6M10.9M10.5M
Retained Earnings(340.8M)(347.4M)(374.9M)(389.9M)(381.5M)(362.5M)
Non Currrent Assets Other2.0M1.8M2.1M1.3M528K501.6K
Common Stock Total Equity144K148K15K35K40.3K62.7K
Other Stockholder Equity270.5M320.3M368.9M379.2M415.0M435.8M
Short Term Debt5.4M59.9M2.4M2.2M23.1M18.6M
Common Stock15K35K46K54K73K62.8K
Accounts Payable6.5M7.2M7.0M5.9M4.3M4.3M
Short Term Investments26K20.3M39.0M5.1M20.9M22.0M
Other Assets2.0M7.4K2.1M1.3M1.00.95
Other Liab20.1M4.0M14.3M1.6M1.5M1.4M
Property Plant Equipment5.3M10.4M9.9M9.6M8.7M8.1M
Current Deferred Revenue16.3M5.4M8.6M13.2M2.9M2.7M
Inventory8.2M13.1M18.0M16.8M19.0M9.6M
Net Tangible Assets(70.3M)(27.0M)(6.0M)(10.6M)(9.6M)(10.1M)
Long Term Debt51.0M51K27.9M28.2M25.4M28.8M
Capital Surpluse270.5M320.3M368.9M379.2M436.0M272.0M
Non Current Liabilities Other5.1M5.3M75.5M51K45.9K43.6K
Long Term Debt Total51.5M51K27.9M28.2M25.4M28.3M
Net Invested Capital(15.1M)31.5M21.9M17.5M53.8M56.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.